Few drug classes have reshaped global pharmaceutical development as rapidly as glucagon-like peptide-1 (GLP-1) receptor agonists. What began as a therapeutic class for type 2 diabetes has expanded through robust clinical evidence into cardiovascular risk reduction, obesity management, and a growing range of cardiometabolic conditions. Dual and triple agonist combinations targeting GIP/GLP-1 and GLP-1/glucagon receptors have further deepened the pipeline.
This clinical expansion has produced a correspondingly complex regulatory landscape. Manufacturers entering new markets with GLP-1 agonist products, whether as originators launching new indications, licensees commercialising established molecules, or developers of biosimilar or follow-on formulations, face a matrix of frameworks, indication-specific evidence requirements, and post-market obligations that differ meaningfully across jurisdictions. Regulatory preparation adequate for the FDA or EMA may be insufficient, improperly formatted, or missing jurisdiction-specific requirements for markets in Asia-Pacific, Latin America, or the Middle East. Understanding where those gaps lie is the starting point for any credible global registration strategy.
Regulatory Classification: The First Decision That Shapes Everything
GLP-1 receptor agonists are peptide-based medicines, synthetic analogues or modified versions of the endogenous incretin hormone GLP-1.
Their classification within regulatory frameworks determines the registration pathway, technical documentation requirements, and post-market obligations that apply.
In the EU, UK, and most ICH-aligned jurisdictions, GLP-1 agonists are regulated as biological medicines. In the US, FDA classifies most GLP-1 agonists as drugs regulated under the Federal Food, Drug, and Cosmetic Act rather than as biologics under the Public Health Service Act, unless the specific product meets the statutory biological definition. This classification distinction has direct consequences: FDA-approved GLP-1 drug products are not subject to the interchangeability framework applicable to biologics, and exclusivity provisions differ accordingly. Manufacturers entering new markets must verify the applicable classification jurisdiction by jurisdiction before committing to a filing strategy.
Injectable GLP-1 agonist products supplied with an integral delivery device, prefilled pens, autoinjectors, and cartridge systems are regulated as combination drug-device products. In the EU, these are primarily regulated as medicines under Directive 2001/83/EC, with the device component reviewed against Medical Device Regulation requirements as part of the medicine’s technical dossier. In the US, the FDA’s combination product framework under 21 CFR Part 3 determines which Centre holds primary jurisdiction. Most other markets regulate the combined product through the drug pathway, with device safety and performance evidence included in the registration dossier. Manufacturers who fail to engage in combination product frameworks early encounter delays, specifically in markets where agency procedures for drug-device applications are less routinely practiced.
Indication-Specific Evidence Requirements
The GLP-1 agonist class holds regulatory approval across multiple distinct indications. Evidence requirements and post-market obligations differ significantly depending on which indication is being pursued.
Type 2 Diabetes
Registration for type 2 diabetes is the most established pathway. Major agencies have well-developed expectations: HbA1c reduction against placebo or active comparator is the primary endpoint, with secondary endpoints covering fasting plasma glucose, body weight change, and proportion of patients achieving glycaemic targets. Cardiovascular outcomes data is a firm requirement following the FDA’s 2008 guidance on cardiovascular risk evaluation in antidiabetic therapies; all GLP-1 agonist products for type 2 diabetes must include pre-specified cardiovascular outcomes analyses. Most major agencies have aligned with equivalent expectations. Clinical dossiers must also include pharmacokinetic and safety data in patients with renal impairment, as both EMA and PMDA have placed label restrictions related to renal function based on available clinical evidence.
Obesity and Chronic Weight Management
FDA’s guidance on weight management drug development specifies total body weight loss from baseline as the primary efficacy endpoint, with requirements for both the magnitude of weight loss and the proportion of patients achieving clinically meaningful thresholds. EMA’s CHMP has broadly aligned with this approach while applying European-specific benefit-risk considerations for the non-diabetic obese population.
For Asia-Pacific markets, the obesity indication introduces a critical complication: BMI cut-off differences. WHO Asian BMI criteria define overweight as ≥23 kg/m² and obesity as ≥25 kg/m², substantially lower than the Western thresholds of ≥25 and ≥30 used in most pivotal trials. Regulatory agencies in Japan (PMDA), South Korea (MFDS), China (NMPA), and Australia (TGA) apply these lower thresholds when assessing whether a trial population adequately represents the local patient group. Sponsors who have not designed pivotal obesity trials to include Asian BMI subgroup analyses face requests for additional data or requirements for local bridging studies, a substantive risk that has materialised in multiple GLP-1 agonist obesity submissions across the region.
Cardiovascular Risk Reduction
Several GLP-1 agonist products hold approval for cardiovascular risk reduction as a primary or co-primary indication in patients with established cardiovascular disease. For manufacturers seeking this indication outside the US and EU, local agency review of the cardiovascular outcomes trial data is substantive. The approved indication language varies between agencies, and agencies in Japan, South Korea, Australia, and Brazil conduct independent assessments of CVOT methodology. Sponsors must review jurisdiction-specific approved indication language carefully when planning a global labelling strategy.
Regional Regulatory Considerations
Japan and South Korea
PMDA expects a systematic ethnic factor analysis under ICH E5 for GLP-1 agonist submissions. Japanese bridging pharmacokinetic studies are expected, where systemic exposure in Japanese patients has not been adequately characterised from multinational trial data. Japan’s SAKIGAKE designation is available for innovative medicines with marked therapeutic improvement in serious conditions, which can accelerate PMDA review timelines and is directly relevant for novel GLP-1 agonist combinations.
South Korea’s MFDS has adopted a progressively more internationally aligned position on foreign clinical data acceptability. Korean-specific post-marketing surveillance commitments typically a re-examination study in Korean patients over four years remain a standard condition of initial marketing authorisation.
China
NMPA has implemented ICH guidelines progressively since joining ICH in 2017 and now accepts multinational trial data as the primary evidence basis for innovative medicine applications. NMPA’s preferred position for GLP-1 agonist submissions is trial data that includes Chinese patients or Chinese trial sites. Where pivotal trials did not include Chinese patients, a bridging pharmacokinetic study in Chinese subjects is typically required.
Australia
TGA evaluates GLP-1 agonist products through the Category 3 verification pathway for products already approved by FDA or EMA, targeting 175 working days from acceptance. The Australian Specific Annex of the Risk Management Plan must address local cardiovascular disease and diabetes epidemiology and Australian-specific safety monitoring requirements. TGA requires explicit discussion of pancreatitis risk in the Product Information and Consumer Medicine Information.
Brazil and GCC
Brazil’s ANVISA recognises FDA and EMA approvals as a basis for priority review, substantially compressing Brazilian registration timelines for reference-approved products. In the Gulf Cooperation Council, Saudi Arabia’s SFDA is the primary market target; it conducts independent scientific assessments and has a specific interest in the GLP-1 class, given the region’s high diabetes prevalence. GCC mutual recognition allows an SFDA registration to support applications in other member states.
Pharmacovigilance and Label Harmonisation
GLP-1 agonist products with multi-market registrations carry pharmacovigilance obligations in every jurisdiction where approved. The class’s known safety profile includes gastrointestinal adverse effects, pancreatitis risk, thyroid C-cell findings from rodent studies, and gallbladder disease, which must be monitored systematically, with jurisdiction-specific reporting to each agency. Effective global pharmacovigilance requires a single global safety database, jurisdiction-specific expedited reporting procedures, periodic safety reports aligned with ICH E2C schedules, and Risk Management Plans maintained for the EU, Korea, Japan, Australia, and other markets. Companies that build pharmacovigilance infrastructure after registration rather than before it are non-compliant from day one.
Approved GLP-1 agonist labels differ between jurisdictions in contraindication language, boxed warning requirements, indication scope, and special population instructions. The global label strategy requires sustained attention; a label developed for the FDA may need substantive revision for EMA, and the EU SmPC requires further adaptation for Japan, South Korea, Australia, and other markets. Tracking and maintaining cross-jurisdictional label consistency across the product lifecycle is a resource-intensive obligation that must be explicitly resourced.
Conclusion
The GLP-1 agonist regulatory landscape rewards manufacturers who engage market-specific requirements with precision rather than extrapolating from FDA or EMA experience alone. Classification, indication-specific evidence packages, ethnic bridging data requirements, combination product frameworks, and multi-market pharmacovigilance all differ meaningfully across jurisdictions. Companies that identify and plan for those differences before filing, rather than during review, achieve timely and durable market access.
How can DDReg help?
DDReg’s regulatory affairs team supports GLP-1 agonist manufacturers across global market entry strategy, indication-specific dossier preparation, ethnic bridging data planning, combination product regulatory coordination, multi-jurisdictional RMP development, and pharmacovigilance infrastructure design across FDA, EMA, PMDA, NMPA, MFDS, TGA, ANVISA, and GCC submissions.
Read more from our experts here: Cell & Gene Therapy in the EU: EMA’s ATMP Regulatory Pathway Unpacked for Manufacturers